lobbying_activities: 2349427

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2349427	bf3c50b8-9655-4b5d-b101-0d6477ef3208	Q3	EMERGENT BIOSOLUTIONS INC.	304931	EMERGENT BIOSOLUTIONS INC	2019	third_quarter	DIS	-FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government -NDAA - provisions related to biological and chemical defense -Department of Defense appropriations for Medical Countermeasures -FDA regulatory issues -Issues related to Priority Review Voucher programs -Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines	HOUSE OF REPRESENTATIVES,SENATE		670000	0	0	2019-10-18T09:48:15.453000-04:00